GSK (FKA GLAXOSMITHKLINE INC.) for GSK (FKA GLAXOSMITHKLINE INC.)
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
H.R. 880American Research and Competitiveness Act of 2015A bill to modify and make permanent the research and development (R&D) tax credit No bill # assignedTax reform policy issuesprovisions related to corporate tax reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| JOSEPH MCGOWAN | — |
| STEPHEN SCANGO | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| SARAH J WALSH | — |
| KIMBERLY A WILLIAMS | — |
Copyright/Patent/Trademark CPT
H.R. 2045H.R. 2045: Targeting Rogue and Opaque Letters Act of 2015 Provisions related to demand letters H.R. 1353 PATIENT Act of 2015 Provisions related to extension of marketing exclusivity H.R. 971 Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 Provisions related to extension of marketing exclusivity S. 1421S. 1421: Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 Provisions related to exclusivity S. 1137 PATENT Act Provisions related to patent litigation reform and post-grant proceedings at the Patent and Trademark Office S. 926 Grace Period Restoration Act of 2015 Provisions related to grace period and patent law S. 632 STRONG Patents Act of 2015 Provisions related to post-grant proceedings, bad faith demand letters, and PTO diversion H.R. 9Innovation Actprovisions related to patent litigation reform S. 131Fair and Immediate Release of Generic Drugs Actprovisions related to patent settlements S. 632STRONG Patents Act of 2015provisions relating to post grant proceedings, bad faith demand letters, and PTO diversion No bill # assignedBiopharmaceutical innovation policy issues No bill # assignedBiologics data protection issues No bill # assignedIntellectual property issues Additional data exclusivity request that was part of 21st Century Cures submission
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| JOSEPH MCGOWAN | — |
| STEPHEN SCANGO | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| SARAH J WALSH | — |
| KIMBERLY A WILLIAMS | — |
Trade (domestic/foreign) TRD
H.R. 1314 Trade Act of 2015 Provisions related to Trade Promotion Authority No bill # assignedTrans-Pacific Strategic Economic Partnership Agreement (TPP)provisions related to intellectual property, market access and public health issues No bill # assignedTransatlantic Trade and Investment Partnership (TTIP)provisions related to market access intellectual property, regulatory harmonization and other issues No bill # assignedInternational market access and intellectual property issues No bill # assignedCanada IP and market access issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| SHIRA KILCOYNE | — |
| JOSEPH MCGOWAN | — |
| STEPHEN SCANGO | — |
| WILLIAM J SCHUYLER | — |
| SARAH J WALSH | — |
| KIMBERLY A WILLIAMS | — |
Health Issues HCR
H.R. 2629 Antibiotic Development to Advance Patient Treatment Act Provisions related to the approval of certain drugs for use in a limited population of patients H.R. 1537H.R. 1537: Advancing Hope Act of 2015 Provisions related to making permanent pediatric rare disease voucher program H.R. 909(CURE) Act Provisions related to expanded access H.R. 880 American Research and Competitiveness At of 2015 Provisions to make permanent the research and development (R&D) tax credit H.R. 786 Vaccine Access, Certainty, and Innovation Act of 2015 Provisions related to vaccine development H.R. 6 21st Century Cures Act Provisions related to biopharmaceutical discovery, development, delivery and transparency S. 1128 Preserving Access to Orphan Drugs Act Provisions related to orphan drug tax (113th Congress) H.R. 1547 Family Health Care Flexibility ActProvisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts No bill # assigned Antibiotic Development to Advance Patient Treatment ActProvisions related to antibiotics and drug approvalAllHouse/Senate S. 836Family Health Care Flexibility Actprovisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts S. 122Safe and Affordable Drugs from Canada Actprovisions related to drug importation S. 185PATH Act provisions related to antibiotics and drug approval S. 320Medical Innovation Act of 2015provisions related to NIH funding and covered manufacturer supplemental fees No bill # assignedImplementation issues relating to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation rulemaking No bill # assigned21st Century Cures Initiative and related policy issues No bill # assignedFDA special medical useissues related to limited population antibacterial drug approval pathway No bill # assignedFDA accelerated approval policy issues No bill # assignedComparative effectiveness policy issues No bill # assignedBiopharmaceutical innovation policy issues No bill # assignedPharmaceutical supply chain security issues No bill # assigned340B policy issue No bill # assignedImplementation issues relating to the Physician Payment Sunshine Act No bill # assignedSupport for COPD national action plan No bill # assignedFDA proposed rule regarding generic drug labeling under the 1984 Hatch-Waxman amendments to the FDCA No bill # assignedFDA proposed rule regarding electronic distribution of Content of Labeling for Human Prescription Drug and Biological product
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| JOSEPH MCGOWAN | — |
| STEPHEN SCANGO | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| SARAH J WALSH | — |
| KIMBERLY A WILLIAMS | — |
Medicare/Medicaid MMM
H.R. 2581 Preservation of Access for Seniors in Medicare Advantage Act of 2015 Provisions related to changes to the Medicare Advantage Program H.R. 2570 Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015Provisions related to changes to the Medicare Advantage Program H.R. 1190 H.R. 1190: Protecting Seniors Access to Medicare Act of 2015 Provisions related to IPAB repeal S. 1369Value-Based Insurance Design Seniors Copayment Reduction Act of 2015 Provisions related to changes to the Medicare Advantage Program S. 1083 Medicare Drug Savings Act of 2015 S. 141 Protecting Seniors' Access to Medicare Act of 2015 Provisions related to Independent Payment Advisory Board (IPAB) repeal S. 31 Medicare Prescription Drug Price Negotiation Act of 2015 Provisions related to Secretary negotiation authority in Part D program H.R. 1190 Protecting Seniors' Access to Medicare Act of 2013provisions related to the Independent Payment Advisory Board H.R. 1470 SGR Repeal and Medicare Provider Payment Modernization Act of 2015Provisions related to SGR reform H.R. 4187 Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) S. 31Medicare Prescription Drug Price Negotiation Act of 2013provisions related to Part D issues S. 141Protecting Seniors' Access to Medicare Act of 2013provisions related to the Independent Payment Advisory Board S. 648Medicare Formulary Improvement Actprovisions related to Medicare Part D No bill # assignedProposals to increase co-payments for Part D beneficiaries receiving the low-income subsidy No bill # assignedIssues related to better use of medicines and comprehensive medication management No bill # assignedVaccine access and coverage issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| JOSEPH MCGOWAN | — |
| STEPHEN SCANGO | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| SARAH J WALSH | — |
| KIMBERLY A WILLIAMS | — |
Budget/Appropriations BUD
Sen. Con. Res 11 amendments relevant to the biopharmaceutical industry including Medicare Part D H. Con. Res. 27 amendments relevant to the biopharmaceutical industry including Medicare Part D H.R 1078 Food and Drug Administration Safety Over Sequestration Act of 2015 - Provisions related to exemption of certain user fees from sequestrationProvisions related to drug reimbursement, Part D, and biopharmaceutical research No bill # assigned2016 Agriculture Appropriations Bill Provisions related to compounding and e-labeling No bill # assignedThe Presidents FY 2016 Budget Provisions related to prescription drug reimbursement and data exclusivity. No bill # assignedFY 2016 Budget Resolution/Budget Control ActProvisions related to spending caps No bill # assignedBudget Control Act Provisions related to drug reimbursement, Part D, and biopharmaceutical research
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| JOSEPH MCGOWAN | — |
| STEPHEN SCANGO | — |
| WILLIAM J SCHUYLER | — |
| JULIE VENNERS CHRISTENSEN | — |
| SARAH J WALSH | — |
| KIMBERLY A WILLIAMS | — |
Tariff (miscellaneous tariff bills) TAR
YTARNo bill # assigned"provisions related to the emporary duty suspension for preparations, such as tablets or chewing gum, intended to assist smokers to stop smoking (provided for in subheading 2106.90.99) "William, Steve, GarySenate
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY HEIMBERG | — |
| STEPHEN SCANGO | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.